Actively Recruiting
Open-label First-in-Human Study of Oral TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with FGFFGFR Pathway Abnormalities
Led by Tyra Biosciences, Inc · Updated on 2026-10-14
125
Participants Needed
16
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TYRA-430, a first-in-class, selective, reversible inhibitor of fibroblast growth factor receptors 3 and 4, in adults with locally advanced or metastatic hepatocellular carcinoma HCC and other advanced solid tumors that have abnormalities in the FGFFGFR pathway. This Phase 1, open-label, multi-center study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor effects of TYRA-430. The study includes a dose escalation phase where participants receive varying oral doses of TYRA-430 daily to determine the maximum tolerated dose. Following this, there are two dose expansion groups one for advanced HCC and another for other advanced solid tumors, both receiving the determined doses. Participants receive TYRA-430 as monotherapy throughout the study. Participants will be monitored for up to one year for maximum tolerated dose and adverse events, with extended follow-up up to two years for pharmacokinetic and pharmacodynamic measures and up to 3.5 years for response outcomes like overall response rate and duration. Assessments include tumor tissue analysis, safety evaluations, and measurement of tumor lesions. The study involves regular visits and monitoring to evaluate response and safety throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Research Team
L
Lara Balick
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here